Start New EnglishEspañol中文РусскийالعربيةTiếng ViệtFrançaisDeutsch한국어Tagalog Library Performance

2025 ICD-10-CM code A30.3

Borderline leprosy (BB leprosy).

Use additional codes to identify any complications or comorbidities (e.g., nerve damage, eye involvement).Do not use Z16.- codes for antimicrobial resistance in conjunction with leprosy codes; instead, query the provider.

Medical necessity for services related to A30.3 is established by the presence of signs and symptoms consistent with borderline leprosy, confirmed by physical examination and diagnostic testing. Treatment is necessary to prevent disease progression, minimize nerve damage, and prevent transmission.

Clinicians diagnose borderline leprosy based on skin lesions (reddish, flat patches with sensory loss), possible enlarged lymph nodes, nerve involvement (numbness, weakness), and sometimes, biopsies. They manage the disease with multi-drug antibiotic therapy and sometimes anti-inflammatory medications.

In simple words: Borderline leprosy is a bacterial infection that affects the skin, nerves, and mucous membranes (like the lining of your nose). It causes reddish patches on the skin with loss of feeling and may lead to other symptoms if it progresses to a more severe form.

A form of leprosy intermediate between the lepromatous and tuberculoid forms.It shares clinical manifestations of both types and may progress towards either extreme. Also known as borderline leprosy or BB leprosy.

Example 1: A patient presents with multiple reddish, irregularly shaped skin patches on their arms and legs with reduced sensation to touch and pain.A skin biopsy confirms Mycobacterium leprae, and the patient is diagnosed with borderline leprosy (A30.3)., A patient initially diagnosed with tuberculoid leprosy experiences worsening symptoms, developing more numerous and diffuse skin lesions and nerve involvement. Their classification is changed to borderline leprosy (A30.3) as the disease progresses., A patient with borderline leprosy (A30.3) shows signs of upgrading reactions, indicating the disease is shifting towards the tuberculoid form. The physician adjusts treatment accordingly to manage the inflammatory response and prevent further nerve damage.

Documentation for A30.3 should include:Detailed description of skin lesions (size, shape, color, location, sensory changes); Results of skin or nerve biopsies; Neurological examination findings (sensory and motor function); Treatment plan (including medications and duration).

** Only Enterprise users with EHR integration can access case-specific answers. Click here to request access.

Discover what matters.

iFrame™ AI's knowledge is aligned with and limited to the materials uploaded by users and should not be interpreted as medical, legal, or any other form of advice by iFrame™.